EDAP's lithotripter approved in Korea
This article was originally published in Clinica
Sonolith i-move, a lithotripter developed by therapeutic ultrasound specialist EDAP TMS (Lyon, France), has been approved for sale by the South Korean Food and Drug Administration (KFDA). Lithotripters break up kidney or other stones using sonic shock waves. The Sonolith i-move has an infrared stereo-vision system for real-time, three-dimensional ultrasound-free localisation of urinary stones. South Korea is the second largest market in Asia for lithotripsy devices, after Japan. The device is awaiting approval in the US and Japan.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.